1D·

The next nail in the coffin?

https://www.n-tv.de/panorama/Mehrere-Abnehmspritzen-Patienten-erleiden-schwere-Sehschaeden-id30053721.html

This can be $NOVO B (+0,28 %) very unpleasant and also expensive.

www.n-tv.deMehrere Abnehmspritzen-Patienten erleiden schwere Sehschäden

18 Comentarios

MEMO@MEMO1993

I have informed myself and Lilly will also suffer the same problem, but it is written on the packaging and the doctors know about it and also the EU -USA nevertheless it was approved, the cases occur 1:10000. This is the case with any medication that rapidly lowers blood sugar. If you have a retinal disease it can worsen. Other type 2 diabetes products also have the same problem and this is not recent. People who need it because they have a disease and need to treat it will still take it. Chemoteraphy also kills everything in the body - there is nothing better on the market.

•

MEMO@MEMO1993

@MEMO1993 Conclusion I am still bullish up to 60-65 euros in the short to medium term, then I would definitely take profits as before. In the long term, the company is doing nothing wrong in research and development. The management has been replaced, the company is restructuring itself and is already developing the next pipeline. Pharma is never safe, nor will it be, regardless of the company. The company has been around since 1989 before the merger in 1923 -1925. 100 years in the insulin market - just like Lilly in the long term, that's a shame. Johnson Johnson has had more shit on its hands.

••

Chris@Multibagger

@MEMO1993 The question will be whether the disease also occurs in people who do not have diabetes but only take the injection to lose weight. If this is the case, these people will think twice.

••

MEMO@MEMO1993

@Multibagger I realize that, but that also applies to Lilly and Novo is also cheaper in terms of the evaluation and the price of the medication. I don't think they're doing it wrong at the moment. Even if I look at the margins, I'd rather see less consumption and a slowly growing market where people can afford it and really treat problems, instead of dayly consumption and no idea what problems arise because someone wants to become a model.

••

MEMO@MEMO1993

@MEMO1993 I really earned a lot with the company this year and before. I take a few swings with me but I leave 50 shares in, I have nothing to lose, they are purely profits, good dividends will be increased by then, it's a small addition to my total capital. Shares are also bought back in good years. Pharma is pharma, small pharma is pure speculation, big pharma often has something in reserve, see ROCHE - is just waking up from the dead. And diabetes is really a field where you can cash in for the next 100 years minimum.

••

Solitair@Solitair

@Multibagger Robbie Williams has that.

••

MEMO@MEMO1993

@Solitair Current health: Recent reports also mention visual disturbances in connection with the use of the slimming drug Mounjaro. so Lilly or Novo?

••

MEMO@MEMO1993

@MEMO1993 this is from Lilly at least from the last 20 news not from Novo, I think Lilly will pull the trigger and Novo will rise xDDDDDDD

••

Solitair@Solitair

@MEMO1993 https://www.zdfheute.de/ratgeber/gesundheit/abnehmspritze-mounjaro-blind-nebenwirkung-robbie-williams-100.html
The one from Lilly. But basically it also affects wegovy from novo

••

Der P.@Panda0404

Ppuuuhh so I'm slowly thinking about getting out. 😑

•

Christian@Gebsen79

$VKTX It's time for the arrow to point steeply upwards here....

••

Max@Divident_e

@Panda0404 buy now more than ever

••

BeachPleases@BeachPlease

@Divident_e Dip, dip, dip

••

Epi@Epi

If it is in the press, it is in the price.

Now we know the reason for the sharp drop in recent weeks and months.

•

Dividendenopi👴@Dividendenopi

Gaaaaanz hot 🔥 iron.... also damn hard to argue here now. It is at least fairly pointed out in the report that diabetics have a higher risk of suffering from visual impairment from the outset. I don't want to have to judge whether a medication is definitely the trigger. Please don't misunderstand me if I'm trying to pin this on Novo alone, like glyphosate and Bayer. There are 60 manufacturers worldwide, most of them in China, that produce glyphosate. One company is being slaughtered. With all due understanding for the individual fates of each company, it would be fatal to back down now. And $LLY would be rubbing its hands together with others, provided the wave of litigation does not spread. The compensation is comparatively harmless and, if there really is causality, ridiculous.

••

Chris@Multibagger

@Dividendenopi that's only so little in Denmark. If such lawsuits were filed in the USA, they would run into the millions.

•

NichtRelevant@NichtRelevant

I am not invested in $NOVO B, but my $BAYN shares are suffering greatly from the legal disputes over glyphosate, which were 'bought in' through the takeover of Monsanto.
Warnings about the proper use of the weedkiller are also printed there. Nevertheless, the litigation industry has turned its attention to Bayer. Especially because courts in the USA award plaintiffs particularly generous compensation if the defendant company is not from their own country.

What I'm saying is that it's possible that there will be no major lawsuits. But it is also possible that the lawyers in the USA are warming up with class actions and $NOVO B is a welcome opponent, as it comes from Europe, which is now hated.

••

Dukke@Dukke

I suspect a Bayer scenario with NOVO

••